A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister
September 20, 2011
-
REGULATORY HSC Subcommittee Agrees on Need for New System to Promote Access to Unapproved Drugs
September 20, 2011
-
REGULATORY Preparations Underway for MHLW to Set Up Private Third-Party Committee
September 16, 2011
-
REGULATORY Council Recommends 5 Drugs as Appropriate for Application Based on Info. in Public Domain
September 16, 2011
-
BUSINESS Small, Medium-Sized Generic Drug Makers’ Business Improves Amid Uncertainty Over Future
September 15, 2011
-
BUSINESS Supreme Court Rules Against GE Drug Makers, Allows Patent Extension for Eisai’s Aricept
September 15, 2011
-
ACADEMIA NCGM Hospital Removes Actos from List of Recommended Drugs in Diabetes Manual
September 14, 2011
-
ORGANIZATION FPMAJ Announces Its Basic Policy on Providing Info. on Drugs Used Off-label
September 13, 2011
-
BUSINESS Takeda Initiates PIII Trials of Antidiabetic TAK-875 in Japan
September 13, 2011
-
BUSINESS NBI Initiates PIII Study for BIBF1122 in Japan
September 12, 2011
-
REGULATORY MHLW Director-General Kikura Indicates “Firm Resolve” for Structural Improvement to Eliminate Drug Disasters
September 12, 2011
-
ACADEMIA Clinical Positioning Needs to Be Clarified for Nexavar, Sutent: Prof. Naito of Kyushu Univ.
September 12, 2011
-
REGULATORY MHLW’s Council to Draw Up 10-Year Strategy for Hepatitis
September 9, 2011
-
REGULATORY Council Recommends Subsidization of Peginterferon Therapy for Chronic Active Hepatitis B
September 9, 2011
-
BUSINESS Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib
September 8, 2011
-
REGULATORY CSIMC Introduces New Rule for Pricing of High-Priced Drugs; 10 Drugs to Be Reimbursed on Piecework under DPC
September 8, 2011
-
REGULATORY Some CSIMC Members Question NHI Pricing of Nexium Priced at Lower Level Than Omepral
September 8, 2011
-
REGULATORY CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 7, 2011
-
ACADEMIA ”Seller’s Market” for Pharmacists Expected to Continue Over Next Few Years
September 7, 2011
-
ORGANIZATION JGA to Prepare Transparency GLs
September 6, 2011
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…